Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

Inclusion Criteria:

* 18 to 70 years of age.
* Body Mass Index (BMI) ≥ 25 at screening.
* BMI ≥ 23 for Asian participants at screening.
* Stable body weight (approximately 5% or less gain or loss) during the 4-week run-in period, unless the study doctor determines otherwise.
* Stable dose of weekly GLP-1RA.
* Stable gastrointestinal (GI) tolerability.
* Contraception for females.
* Stable for 3 months if obstructive sleep apnea (OSA), hypertension, hyperlipidemia, and/or hypothyroidism.
* Willingness to follow trial procedures for the duration of the trial.

Exclusion Criteria:

* Type 1/Type 2 diabetes mellitus (DM).
* Obesity induced by other endocrine disorder (ex: Cushing's syndrome).
* History of malignancy in the last 5 tears except for nonmelanoma skin cancers, cervical, or breast ductal carcinoma in situ.
* Acute \& chronic pancreatitis within 1 year.
* Uncontrolled thyroid disease.
* Gastroparesis or gastric outlet obstruction.
* Surgery for obesity in the last 6 months.
* Heart attack within 3 months.
* History of ischemic optic neuropathy.
* Positive HIV or certain positive Hepatitis B or hepatitis C.
* Current use of compounded weekly GLP-1RA.
* Previous participation in Maridebart cafraglutide trial.
* Alcohol or drug abuse.
* Pregnancy, breastfeeding, or planning to breastfeed.